Company Overview
Myriad Genetics, Inc. operates as a molecular diagnostics and precision medicine company that develops and offers molecular diagnostic tests specifically for oncology, women's health, and pharmacogenomics. The company also provides the MyRisk Hereditary Cancer test, which utilizes DNA sequencing to identify risks associated with hereditary cancers, alongside a BRA test offering further diagnostic capabilities. This entity functions within the broader Healthcare sector, specifically targeting the Diagnostics & Research industry, where it focuses on translating genomic data into clinical applications for patient care. As of the latest reporting period, the company holds a market capitalization of $437.62M and generates annual revenue of $824.50M while employing approximately 2,700 individuals. These financial figures, particularly the market cap relative to revenue, indicate that the company operates on a mid-cap scale where valuation is significantly influenced by future growth expectations rather than current profitability, positioning it as a specialized player in the genomic testing landscape.
Financial Health
The company reported trailing twelve-month revenue of $824.50M, yet it recorded a net income loss of -$365,900,000 and an EBITDA of -$14,100,000, revealing a substantial gap between top-line generation and bottom-line profitability that points to a heavy cost structure or one-time charges impacting the income statement. Despite the operating losses, the company maintains a positive free cash flow of $762,500, which provides a degree of financial flexibility by allowing management to fund operations or reduce debt without immediate external financing. The margin profile presents a mixed picture, with a gross margin of 69.9% indicating efficient core product production, contrasted by a negative operating margin of -1.4% and a steep profit margin of -44.4% that highlights significant overhead or restructuring costs erding operating profits. On the balance sheet, the company holds $149.60M in cash against $209.80M in debt, resulting in a debt-to-equity ratio of 57.01, which suggests a leveraged position where debt obligations are substantial relative to shareholder equity. Liquidity is supported by a current ratio of 2.49, indicating that the company possesses more than double the current assets necessary to cover its short-term liabilities. However, the return metrics reflect the financial strain, with a return on equity of -68.5% and a return on assets of -4.9%, signaling that current management effectiveness has resulted in value destruction rather than capital appreciation over the trailing period.
Valuation Assessment
Valuation metrics for Myriad Genetics show a trailing P/E ratio of N/A due to negative earnings, while the forward P/E stands at 27.60, implying that the market is pricing in anticipated future earnings recovery despite current losses. The price-to-book ratio is 1.19, indicating that the market values the company at a slight premium over its net asset value, which may reflect confidence in intangible assets or future revenue streams not captured on the books. Alternative valuation measures include a price-to-sales ratio of 0.53 and an EV/EBITDA of -35.31, which suggests the stock is priced at less than one times its sales, a common characteristic for loss-making biotech firms where revenue quality is scrutinized more heavily than earnings. The stock trades between a 52-week high of $10.26 and a 52-week low of $3.76, and given the forward P/E of 27.60 and the current market cap of $437.62M, the price sits within a volatile range that reflects high uncertainty about when profitability will be restored. The beta value of 1.93 indicates that the stock exhibits high price volatility, moving nearly twice as much as the broader market in either direction, which necessitates a higher risk premium from investors.
Growth & Income
Revenue growth is recorded at -0.4% year-over-year, while earnings growth is listed as N/A due to the absence of reported earnings in the trailing period, meaning there is no positive earnings trajectory to compare against revenue changes. Since the company does not pay a dividend, the dividend yield is N/A and the payout ratio is 0.0%, which confirms that the firm retains all available cash flow rather than distributing it to shareholders. The absence of a dividend payout ratio implies that earnings are not being distributed, but instead the company is in a phase where capital preservation or strategic reinvestment is prioritized over income generation for investors. The overall growth and income profile is characterized by negative revenue momentum and a lack of current income generation, relying entirely on potential future operational improvements to restore profitability and potentially initiate a dividend policy in the future.